Revenue Breakdown
Composition ()
No data
Revenue Streams
IDEAYA Biosciences Inc (IDYA) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is WRN, accounting for 56.0% of total sales, equivalent to $2.20M. Other significant revenue streams include MAT2A and Pol Theta. Understanding this composition is critical for investors evaluating how IDYA navigates market cycles within the Biotechnology & Medical Research industry.
Profitability & Margins
Evaluating the bottom line, IDEAYA Biosciences Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 52.18%, while the net margin is 57.37%. These profitability ratios, combined with a Return on Equity (ROE) of -14.15%, provide a clear picture of how effectively IDYA converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, IDYA competes directly with industry leaders such as ALMS and VRDN. With a market capitalization of $2.88B, it holds a significant position in the sector. When comparing efficiency, IDYA's gross margin of 100.00% stands against ALMS's 100.00% and VRDN's 100.00%. Such benchmarking helps identify whether IDEAYA Biosciences Inc is trading at a premium or discount relative to its financial performance.
